Search results
Results From The WOW.Com Content Network
The US National Osteoporosis Foundation recommends pharmacologic treatment for patients with hip or spine fracture thought to be related to osteoporosis, those with BMD 2.5 SD or more below the young normal mean (T-score -2.5 or below), and those with BMD between 1 and 2.5 SD below normal mean whose 10-year risk, using FRAX, for hip fracture is ...
Senile osteoporosis has been recently recognized as a geriatric syndrome with a particular pathophysiology. There are different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. [1]
The trabecular bone score is a measure of bone texture correlated with bone microarchitecture and a marker for the risk of osteoporosis.Introduced in 2008, [1] its main projected use is alongside measures of bone density in better predicting fracture risk in people with metabolic bone problems.
Archives of Osteoporosis is a peer-reviewed medical journal published by Springer Science+Business Media. [1] It was established in 2006 and is an official journal of the International Osteoporosis Foundation and the United States' National Osteoporosis Foundation . [ 1 ]
Osteopenia, known as "low bone mass" or "low bone density", is a condition in which bone mineral density is low. [1] Because their bones are weaker, people with osteopenia may have a higher risk of fractures, and some people may go on to develop osteoporosis. [2]
The International Osteoporosis Foundation (IOF), headquartered in Nyon, Switzerland, is a non-governmental organization (NGO) founded in 1998. It was formed from the merger of the European Foundation for Osteoporosis, founded in 1987, and the International Federation of Societies on Skeletal Diseases. [1]
Osteosclerosis is a disorder characterized by abnormal hardening of bone and an elevation in bone density. It may predominantly affect the medullary portion and/or cortex of bone.
Evenity/Romosozumab is a relatively new treatment for osteoporosis approved in 2019. A little bit more detailed information also on the page on Sclerostin. I think the osteoporosis section on medication should include mention of this new treatment, but it is already very well-structured and I don't really know where it would fit.